GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » PB Ratio

Adaptive Biotechnologies (Adaptive Biotechnologies) PB Ratio

: 1.14 (As of Today)
View and export this data going back to 2019. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-17), Adaptive Biotechnologies's share price is $2.43. Adaptive Biotechnologies's Book Value per Share for the quarter that ended in Dec. 2023 was $2.13. Hence, Adaptive Biotechnologies's PB Ratio of today is 1.14.

Good Sign:

Adaptive Biotechnologies Corp stock PB Ratio (=1.3) is close to 5-year low of 1.21

The historical rank and industry rank for Adaptive Biotechnologies's PB Ratio or its related term are showing as below:

ADPT' s PB Ratio Range Over the Past 10 Years
Min: 1.15   Med: 4.53   Max: 20.29
Current: 1.15

During the past 7 years, Adaptive Biotechnologies's highest PB Ratio was 20.29. The lowest was 1.15. And the median was 4.53.

ADPT's PB Ratio is ranked better than
73.23% of 1311 companies
in the Biotechnology industry
Industry Median: 2.4 vs ADPT: 1.15

During the past 12 months, Adaptive Biotechnologies's average Book Value Per Share Growth Rate was -34.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -26.70% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Adaptive Biotechnologies was -10.70% per year. The lowest was -26.70% per year. And the median was -18.70% per year.

Back to Basics: PB Ratio


Adaptive Biotechnologies PB Ratio Historical Data

The historical data trend for Adaptive Biotechnologies's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only 6.56 10.95 6.57 2.36 2.30

Adaptive Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 3.00 2.45 2.18 2.30

Competitive Comparison

For the Biotechnology subindustry, Adaptive Biotechnologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's PB Ratio distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's PB Ratio falls into.



Adaptive Biotechnologies PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Adaptive Biotechnologies's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.43/2.126
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Adaptive Biotechnologies  (NAS:ADPT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Adaptive Biotechnologies PB Ratio Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
Kyle Piskel officer: Principal Accounting Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood officer: Chief Commercial Officer, MRD C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams officer: Chief Operating Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg director C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy director 5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno officer: Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102

Adaptive Biotechnologies (Adaptive Biotechnologies) Headlines

From GuruFocus